Network pharmacology analysis: the role of astragaloside IV in rectal cancer
Integrate Medicine · 30.05.2025
DOI: 10.61958/imwb2799 ↗Kurz gefasst
Fachartikel in der Zeitschrift Integrate Medicine, online erschienen am 30.05.2025. Verfasst von Ya Li. Die Arbeit nennt 29 Literaturangaben.
Abstract (Originalsprache)
Objective
Rectal cancer accounts for about one-third of new colorectal cancer cases. While surgery is the main treatment, minimally invasive procedures are better suited for early-stage tumors, and effective drugs remain limited. Astragaloside IV (AS-IV), a key compound from Astragalus membranaceus, shows potential against rectal cancer. In this study, by conducting network pharmacology analyses, we aim to assess its therapeutic effect and support improved outcomes.
Methods
Genes related to rectal cancer and AS IV were collected from GeneCards, ETCM, TCMSP, and HERB databases. Cross-targets were identified using Venn analysis in jvenn and subjected to enrichment analysis via Metascape, including Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Gnomes (KEGG) pathway analyses through MicrobiomeAnalyst. Protein–protein interaction (PPI) networks of the cross-targets were analyzed using STRING and visualized in Cytoscape, where the top 10 hub genes were identified using the MCC algorithm.
Results
Genes related to rectal cancer and AS IV were collected from GeneCards, ETCM, TCMSP, and HERB databases, yielding 3,187, 1,514, and 49 targets, respectively. Venn analysis identified 32 intersecting targets. GO enrichment analysis revealed involvement in processes such as apoptotic signaling and oxygen response, while KEGG pathways were primarily associated with lipid metabolism, atherosclerosis, and non-alcoholic fatty liver disease. A “astragaloside–rectal cancer–cross-target–KEGG” network was constructed using Cytoscape, and ten hub genes were identified using the MCC algorithm: interleukin-6 (IL6), tumor necrosis factor (TNF), AKT serine/threonine kinase 1 (AKT1), B-cell lymphoma 2 (BCL2), hypoxia inducible factor 1 subunit alpha (HIF1A), matrix metallopeptidase 9 (MMP9), interleukin-1 beta (IL1B), transforming growth factor beta 1 (TGFB1), nuclear factor kappa B subunit 1 (NFKB1), and peroxisome proliferator-activated receptor gamma (PPARG).
Conclusions
AS-IV, the main active compound of Astragalus membranaceus, shows therapeutic potential against rectal cancer.
Zitieren
APA
Li, Y. (2025). Network pharmacology analysis: the role of astragaloside IV in rectal cancer. Integrate Medicine. https://doi.org/10.61958/imwb2799
Vancouver
Li Y. Network pharmacology analysis: the role of astragaloside IV in rectal cancer. Integrate Medicine. 2025. doi:10.61958/imwb2799
BibTeX
@article{Li2025,
author = {Li, Ya},
title = {Network pharmacology analysis: the role of astragaloside IV in rectal cancer},
journal = {Integrate Medicine},
year = {2025},
doi = {10.61958/imwb2799}
}
EUVIMED